RB

Reetika Bhardwaj

Associate at ARCH Venture Partners

Greater Chicago Area

Overview 

Reetika Bhardwaj is a Senior Associate at ARCH Venture Partners in the Greater Chicago Area, with a background in business development, scientific communications, and marketing. She has played a key role in supporting various startups and ventures, including serving as a Board Observer for companies like Pretzel Therapeutics and Moleculent. Bhardwaj holds a Master of Business Administration from The University of Chicago Booth School of Business and has made significant investments in the pharmaceuticals and biotech sectors, focusing on Series A and seed-stage companies in the Midwest region.

Work Experience 

  • Senior Associate

    2019 - Current

    Associate 2020-2022 Senior Associate 2023-now - Dedicated to company building and direct investing into disruptive life sciences companies across indications, technologies, and modalities -Source and evaluate investment opportunities across biotech and life sciences that have signifcant impact on human health -Create new ventures and operate within portfolio companies. Investments: Pretzel, AIRNA, Moleculent, Protillion, Metsera, KoreAx, Cytrellis Operations: Walden, Tenvie, Cytrellis, Pretzel

ARCH is a venture firm that focuses on life science discoveries to prevent, detect, and cure disease.

  • Board Observer

    2021

    -Investment and company formation of Pretzel -Business development, Competitive intelligence

Pretzel Therapeutics mission is to develop groundbreaking therapies to reverse mitochondrial dysfunction through mitochondrial biology.

Raised $72,500,000.00 from University of Cambridge Enterprise, Karolinska, Google Ventures, Mubadala Capital Ventures, Angelini Ventures, Invus, EIR Ventures, HealthCap, ARCH Venture Partners and GU Ventures.

  • Board Observer

    2022

    -Direct Investment, syndicate formation -Business development, strategy, operations, competitive intelligence, and chief of staff duties for early stage RNA editing company, from seed through Series B -Indication selection, TPP

  • Board Observer

    2024

    - Direct investment - Portfolio support

  • Board Observer

    2023

Protillion Biosciences specializes in the design and development of protein-based drugs.

Raised $18,000,000.00 from Illumina Ventures and ARCH Venture Partners.

  • Board Member

    2021

    - Investor relations -Commercial operations and strategy

  • Innovation Fund Associate

    2019 - 2020

    • Perform due diligence on a Sleep disorder therapeutics and a pediatric insomnia device company; analyzing potential market, reviewing technology, and assessing development milestone • Advised advisory committee to invest $250K per startup from a $20 M seed fund ; the companies were successfully funded • Served in a venture capital associate role in order to equip the Shultz Innovation Fund Advisory Committee to make investment decisions

UChicagoTech launched the Innovation Fund in 2010 to accelerate the commercialization of promising.

  • Investment Banking Associate (M&A)

    2019 - 2019

Credit Suisse Group is a financial services company that advises clients in all aspects of finance.

  • I-Corp Fellow

    2018 - 2019

    Business Development Lead for early stage startups in the field of Neuroscience- Alzheimer and Sleep Apnea

  • Scientific Advisor and Business Development

    2015 - 2018

Spectrums unique business approach is working our clients know it, our veteran and newly hired team members.

Articles About Reetika

Relevant Websites